Ken Takanashi Net Worth

The estimated Net Worth of Ken Takanashi is at least $147 million dollars as of 6 June 2023. Mr. Takanashi owns over 22,053,581 units of Wave Life Sciences stock worth over $146,601,395 and over the last 8 years he sold WVE stock worth over $0. In addition, he makes $151,328 as Independent Director at Wave Life Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Takanashi WVE stock SEC Form 4 insiders trading

Ken has made over 2 trades of the Wave Life Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 22,053,581 units of WVE stock worth $20,068,759 on 6 June 2023.

The largest trade he's ever made was buying 22,053,581 units of Wave Life Sciences stock on 6 June 2023 worth over $20,068,759. On average, Ken trades about 1,591,922 units every 97 days since 2016. As of 6 June 2023 he still owns at least 24,847,694 units of Wave Life Sciences stock.

You can see the complete history of Mr. Takanashi stock trades at the bottom of the page.

Ken Takanashi biography

Ken Takanashi CPA serves as Independent Director of the Company. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd., or “SNBL,” and its affiliates and currently serves as its Executive Vice President, Chief Operating Officer. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014. Mr. Takanashi also serves on the board of directors of Satsuma Pharmaceuticals, Inc. a public biopharmaceutical company. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor’s degree from the University of Tokyo and is a Chartered Public Accountant.

What is the salary of Ken Takanashi?

As the Independent Director of Wave Life Sciences, the total compensation of Ken Takanashi at Wave Life Sciences is $151,328. There are 13 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.

How old is Ken Takanashi?

Ken Takanashi is 56, he's been the Independent Director of Wave Life Sciences since 2012. There are 5 older and 13 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.

Insiders trading at Wave Life Sciences

Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ... et Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.

What does Wave Life Sciences do?

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.

Complete history of Mr. Takanashi stock trades at Wave Life Sciences et Satsuma Pharmaceuticals

Wave Life Sciences executives and stock owners

Wave Life Sciences executives and other stock owners filed with the SEC include:

• Paul Bolno,
  President, Chief Executive Officer, Director
• Christopher Francis,
  Senior Vice President - Corporate Development, Head of Emerging Areas
• Michael Panzara,
  Chief Medical Officer
• Chandra Vargeese,
  Senior Vice President, Head of Drug Discovery
• Dr. Paul B. Bolno M.B.A., M.D., MBA,
  Pres, CEO & Director
• Dr. Michael A. Panzara M.D., M.P.H., MPH,
  Chief Medical Officer and Head of Therapeutics Discovery & Devel.
• Dr. Chandra Vargeese Ph.D.,
  Chief Technology Officer
• Gregory Verdine,
  Director
• Mark Corrigan,
  Independent Director
• Amy Pott,
  Independent Director
• Heidi Wagner,
  Independent Director
• Christian Henry,
  Independent Chairman of the Board
• Peter Kolchinsky,
  Independent Director
• Ken Takanashi,
  Independent Director
• Adrian Rawcliffe,
  Independent Director
• Koji Miura,
  Independent Director
• Kenneth Rhodes,
  Senior Vice President - Therapeutics Discovery
• David Gaiero,
  Interim Chief Financial Officer
• Kate Rausch,
  Investor Relations
• Anne-Marie Li-Kwai-Cheung,
  Sr. VP of Regulatory Affairs, Compliance & Policy
• Dr. Sridhar Vaddeboina Ph.D.,
  Sr. VP of Chemistry, Manufacturing & Controls
• Jose Juves,
  Sr. VP of Corp. Affairs & Patient Advocacy
• Jonathan Rosin,
  Chief HR Officer
• Dr. Christopher Francis Ph.D.,
  Sr. VP of Corp. Devel. & Head of Emerging Areas
• Linda Rockett J.D.,
  Gen. Counsel
• Kyle B. Moran CFA,
  CFO & Principal Accounting Officer
• Chris Francis,
  See Remarks
• Plc Gsk,
  10% owner
• Keith Regnante,
  Chief Financial Officer
• Takeshi Wada,
  Director
• Ken Shin Nippon Biomedical ...,
  
• Masaharu Kagoshima Shinsang...,
  
• Roberto Guerciolini,
  See Remarks
• Masaharu Tanaka,
  Director
• Peter Kolchinsky,
  Director
• Capital Management, Llc Kol...,
  
• Mark Baldry,
  Chief Commerical Officer
• Capital Management, L.P.Ra ...,
  
• Kyle Moran,
  Chief Financial Officer
• Aik Na Tan,